Our Board of Directors
Bob Woods is the Chairman and CEO of Targeted Growth, Inc. Mr. Woods is a highly-respected leader of the global agriculture industry, having served in executive positions at several major ag chemical and seed companies, including Chairman of Syngenta Corp – US and Group President of Zeneca/ICI Ag Products. Mr. Woods is a past Chairman of Crop Life America (CLA) and the Council for Biotechnology. He has received numerous industry awards including CLA’s highest honor, the Lea S. Hitchner Service Award. He currently serves on the boards of Gowan Company, Vertellus Specialties, Inc. and Athena Biotechnologies.
Professor Simon G. Best, OBE, FRSE
Professor Best has nearly 30 years’ experience of raising finance, building companies and commercializing products in the chemical industry and red, green and white biotechnology sectors. He founded two major bio-pharmaceutical businesses; at Ardana he took the company public on the London Stock Exchange, and at Roslin Biomed he commercialized the technology used to create Dolly the Sheep, and merged with the US NASDAQ-listed biotech company Geron Corp. Earlier in his career, Simon was CEO of Zeneca Plant Science (ZPS), which successfully launched the only consumer-labeled GM food in Europe. He recently completed a strategic redirection of the Marine Biotechnology Company – Aquapharm – to focus on oncology drug discovery.
His involvement in Industrial Biotechnology started in the 1990’s with a program at ZPS to genetically modify fast-growing trees to reduce the environmental impact of the paper industry. Between 2007-2009 he was a Director of the enzyme/protein optimization company Direvo Gmbh in Cologne and between 2008-2010 was a Director of Targeted Growth Inc. In December 2012, he was appointed to the Advisory Board of the Fraunhofer Center for System Biology in Santiago, Chile.
In 2008 he co-founded PAR Equity LLP in Edinburgh, Scotland which has raised capital for 16 tech-media, software, medical device, renewable-energy and consumer companies as well as forestry and property funds. He is on the Boards of 2 pioneering companies backed by PAR in Digital Pathology – PATH XL Ltd. in Belfast and in agricultural LED lighting technologies – Greengage Ltd. – in London.
Prof. Best was the Chairman of the UK BioIndustry Association (BIA) in 2006 and 2007 and the Vice-Chairman of BIO in the US from 1994-96 and a member of its Board and Chair of its Bioethics Committee from 1998-2005. In June 2008, he was awarded the Order of the British Empire (OBE) in the Queen’s Birthday Honors List.
Margaret McCormick, Ph.D., Chief Executive Officer, Director
Dr. McCormick leads the overall strategic direction, research and operations of Matrix Genetics. Dr. McCormick successfully spun Matrix Genetics out of Targeted Growth, Inc. where she managed the company’s R&D operations as well as led various company-wide efforts including legislative and intellectual property strategy. Prior to joining TGI, Dr. McCormick was a partner with Integra Ventures where she led Integra’s biotechnology investment strategy and its investment in TGI. Prior to joining Integra, she was the founding president and COO of Sapphire Therapeutics (formerly Rejuvenon Corp.). Earlier in her career she was a consultant with McKinsey & Company. Dr. McCormick earned a Ph.D. in Biology (with a focus on metabolic engineering) from the Massachusetts Institute of Technology and a BS degree from the University of Wisconsin – Madison. She is a past Chair, and current board member of the Algae Biomass Organization, the trade association for the US algae industry.
Carl Weissman, Director
Carl Weissman is a 19 year veteran of the biotechnology industry, working both in venture capital and in companies. He currently is Acting Chief Executive Officer of OSS Healthcare. Prior to this, Carl was the CEO of Accelerator Corporation, and biotechnology investment and management company that he helped found with MPM Capital in 2003. At Accelerator, he sourced, served on the board of, and led the active day-to-day management of twelve companies. One of those companies, Oncofactor, is based upon technology that Carl invented himself identifying completely novel new targets for cancer. He raised over $40 million for Series A investments in these emerging companies, and helped to raise more than $200 million in follow-on financings in the successful “graduates” of Accelerator. During his tenure at Accelerator, Carl also became a Managing Director at OVP Venture Partners, a successful venture capital firm with more than 25 years investing in Northwestern companies. Carl was a partner in funds VI and VII and led investments in Novomer, Fate Therapeutics, Limerick, and Verdezyne, serving on the boards of Novomer and Fate and as an observer at Limerick and Verdezyne. In addition, as a Managing Director at OVP, Carl led investments in and served on the boards of Accelerator graduates VLST Corp. and Allozyne, Inc. Prior to Accelerator, Carl was a Venture Partner at MPM Capital, in which role he acted as the CEO of Centagenetix, Inc., a company he led into a merger with Elixir Pharmaceuticals in 2003 where he remained on the board until 2005. Prior to MPM Capital, Carl held various roles at Prolinx, Inc., a Bothell, Washington based chemistry tools company. Carl departed as the head of Finance, Business Development, and Administration to join MPM Capital.